187.34
price up icon0.05%   0.09
pre-market  Pre-market:  187.10   -0.24   -0.13%
loading
Abbvie Inc stock is traded at $187.34, with a volume of 4.38M. It is up +0.05% in the last 24 hours and down -5.61% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$187.25
Open:
$188.41
24h Volume:
4.38M
Relative Volume:
0.58
Market Cap:
$330.92B
Revenue:
$57.37B
Net Income/Loss:
$4.20B
P/E Ratio:
79.72
EPS:
2.35
Net Cash Flow:
$15.39B
1W Performance:
+2.32%
1M Performance:
-5.61%
6M Performance:
+6.17%
1Y Performance:
+15.54%
1-Day Range:
Value
$187.27
$190.18
1-Week Range:
Value
$182.69
$190.18
52-Week Range:
Value
$162.16
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
55,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2025-04-25
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
187.34 323.41B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
765.84 645.82B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.22 366.76B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
116.94 220.95B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
72.04 304.82B 43.59B 15.04B 10.74B 3.3766

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
Jun 04, 2025

CEREVEL ALERT: Bragar Eagel & Squire, P.C. is Investigating Cerevel Therapeutics Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jun 04, 2025
pulisher
Jun 04, 2025

Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. (ABBV) - TradingView

Jun 04, 2025
pulisher
Jun 04, 2025

Alzheimers Drugs Market Is Booming So Rapidly 2025-2032 - openPR.com

Jun 04, 2025
pulisher
Jun 03, 2025

ABBV: Bullish Momentum Evident in AbbVie Options Activity | ABBV Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

AbbVie call volume above normal and directionally bullish - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Investing News Network

Jun 03, 2025
pulisher
Jun 03, 2025

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals | ABBV Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | ABBV Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals - Longview News-Journal

Jun 03, 2025
pulisher
Jun 02, 2025

Immunology Market Deep Research Report Signals Rapid GrowthAbbVie Inc., Johnson & Johnson - openPR.com

Jun 02, 2025
pulisher
May 31, 2025

How Is AbbVie's Stock Performance Compared to Other Pharmaceuticals Stocks? - MSN

May 31, 2025
pulisher
May 31, 2025

AbbVie Inc. (ABBV) and Chicago Cubs Launch “Striking Out Cancer” Campaign - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

AbbVie announces multi-year partnership with the Chicago Cubs - TipRanks

May 31, 2025
pulisher
May 30, 2025

AbbVie (ABBV) Gains As Market Dips: What You Should Know - Yahoo Finance

May 30, 2025
pulisher
May 30, 2025

Final Trades: JPMorgan, Meta, Abbvie and Gap - CNBC

May 30, 2025
pulisher
May 30, 2025

AbbVie (ABBV) Partners with Chicago Cubs for Cancer Awareness Initiative | ABBV Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbbVie Partners with Chicago Cubs on "Striking Out Cancer" | ABB - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to Join – Contact Levi & Korsinsky - TradingView

May 30, 2025
pulisher
May 30, 2025

AbbVie’s ADC win shows how pharma can break through in solid tumors - Pharma Voice

May 30, 2025
pulisher
May 30, 2025

AbbVie (ABBV) Stock Dips in Morning Trade: What Key Numbers Reveal - Daily Chhattisgarh News

May 30, 2025
pulisher
May 30, 2025

Analyst recommendations: AbbVie, Emerson Electric, Marriott International, Zscaler, and Monster Beverage… - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

AbbVie Partners with Chicago Cubs on "Striking Out Cancer" - PR Newswire

May 30, 2025
pulisher
May 30, 2025

How Is AbbVie's Stock Performance Compared To Other Pharmaceuticals Stocks? - Barchart.com

May 30, 2025
pulisher
May 30, 2025

Berenberg Adjusts Price Target on AbbVie to $170 From $195, Maintains Hold Rating - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands - Nasdaq

May 30, 2025
pulisher
May 30, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com

May 30, 2025
pulisher
May 29, 2025

Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical - MSN

May 29, 2025
pulisher
May 29, 2025

Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc.(ABBV) - TradingView

May 29, 2025
pulisher
May 29, 2025

AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip? - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

AbbVie: Fairly Valued, But Lacking A Spark - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Cancer Therapeutics Market Is Booming So Rapidly 2025-2032 - openPR.com

May 29, 2025
pulisher
May 29, 2025

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat - Yahoo Finance

May 29, 2025
pulisher
May 28, 2025

Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.

May 28, 2025
pulisher
May 28, 2025

AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Bearish Sentiment and Increased Put Activity for AbbVie (ABBV) | - GuruFocus

May 28, 2025
pulisher
May 28, 2025

AbbVie put volume heavy and directionally bearish - TipRanks

May 28, 2025
pulisher
May 28, 2025

Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies - BioSpace

May 28, 2025
pulisher
May 28, 2025

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - sharewise

May 28, 2025
pulisher
May 28, 2025

Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

AbbVie’s Allergan cuts over 200 staff after botched marketing campaign - PharmaLive

May 28, 2025
pulisher
May 28, 2025

AbbVie’s Allergan Cuts Over 200 Staff After Botched Marketing Campaign - BioSpace

May 28, 2025
pulisher
May 27, 2025

AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit - MSN

May 27, 2025
pulisher
May 27, 2025

AbbVie To Present Cancer Trial Data At Upcoming ASCO Event - Benzinga

May 27, 2025
pulisher
May 27, 2025

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio - Investing News Network

May 27, 2025
pulisher
May 27, 2025

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio | ABBV Stock News - GuruFocus

May 27, 2025
pulisher
May 26, 2025

Tissue Engineering Market Generated Opportunities, Future - openPR.com

May 26, 2025
pulisher
May 26, 2025

Prurigo Nodularis Market - GlobeNewswire Inc.

May 26, 2025
pulisher
May 26, 2025

AbbVie’s SWOT analysis: biopharma giant faces pipeline challenges amid stock growth - Investing.com

May 26, 2025

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$153.22
price down icon 0.78%
drug_manufacturers_general NVS
$116.94
price up icon 0.86%
drug_manufacturers_general NVO
$72.04
price up icon 1.59%
drug_manufacturers_general MRK
$78.27
price up icon 1.46%
drug_manufacturers_general GSK
$40.80
price up icon 0.84%
Cap:     |  Volume (24h):